Proposed Placing & Subscription to raise £1.05m

AI SummaryClose X

TheraCryf plc announced a proposed capital raise of approximately £1.05 million through a placing and subscription of new ordinary shares at 0.18 pence each, alongside a share subdivision. The proceeds will fund the completion of the clinic-enabling program for its lead Orexin-1 antagonist addiction asset, aiming to secure a partnering deal. The company has also filed a process patent that could extend commercial protection until 2046 and identified an accelerated pathway for Phase 1 clinical trials in Australia, extending its cash runway to the end of Q1 2027.

Disclaimer*

UK 100